share_log

Recursion Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(8.82%)

Recursion Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(8.82%)

Recursion Pharmaceuticals | SC 13G/A:超過5%持股股東披露文件(修正)-The Vanguard Group(8.82%)
美股SEC公告 ·  11/04 13:30

Moomoo AI 已提取核心訊息

The Vanguard Group has filed an amended Schedule 13G/A with the Securities and Exchange Commission, indicating a change in their holdings of Recursion Pharmaceuticals Inc. As of September 30, 2024, The Vanguard Group reported beneficial ownership of 24,272,798 shares of Recursion Pharmaceuticals' common stock, representing 8.82% of the class. This filing, made under Rule 13d-1(b), shows that The Vanguard Group has shared voting power over 423,218 shares and sole dispositive power over 23,610,916 shares, with an additional shared dispositive power over 661,882 shares. The Vanguard Group, based in Pennsylvania, is an investment adviser and reports that its clients have the right to receive dividends or proceeds from the sale of the reported securities.
The Vanguard Group has filed an amended Schedule 13G/A with the Securities and Exchange Commission, indicating a change in their holdings of Recursion Pharmaceuticals Inc. As of September 30, 2024, The Vanguard Group reported beneficial ownership of 24,272,798 shares of Recursion Pharmaceuticals' common stock, representing 8.82% of the class. This filing, made under Rule 13d-1(b), shows that The Vanguard Group has shared voting power over 423,218 shares and sole dispositive power over 23,610,916 shares, with an additional shared dispositive power over 661,882 shares. The Vanguard Group, based in Pennsylvania, is an investment adviser and reports that its clients have the right to receive dividends or proceeds from the sale of the reported securities.
衛塞哥斯集團已向證券交易委員會提交修訂後的13G/A表,表明他們持有Recursion Pharmaceuticals Inc的股份發生了變化。截至2024年9月30日,衛塞哥斯集團報告持有Recursion Pharmaceuticals普通股的受益所有權爲24,272,798股,佔該類別的8.82%。根據13d-1(b)規定進行的此項申報顯示,衛塞哥斯集團共享423,218股的表決權,並獨自擁有23,610,916股的行使權,另外還共享661,882股的行使權。總部位於賓夕法尼亞的衛塞哥斯集團是一家投資顧問,報告稱其客戶有權獲得股息或出售證券所得的收益。
衛塞哥斯集團已向證券交易委員會提交修訂後的13G/A表,表明他們持有Recursion Pharmaceuticals Inc的股份發生了變化。截至2024年9月30日,衛塞哥斯集團報告持有Recursion Pharmaceuticals普通股的受益所有權爲24,272,798股,佔該類別的8.82%。根據13d-1(b)規定進行的此項申報顯示,衛塞哥斯集團共享423,218股的表決權,並獨自擁有23,610,916股的行使權,另外還共享661,882股的行使權。總部位於賓夕法尼亞的衛塞哥斯集團是一家投資顧問,報告稱其客戶有權獲得股息或出售證券所得的收益。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息